Breastfeeding mothers should steer clear of aspirin

Breastfeeding mothers are advised against taking aspirin, especially in high doses for pain relief. This is because aspirin has been linked to Reye’s syndrome, a condition that can result in liver and brain harm.

Breastfeeding has some contraindications that are important to know, especially when it comes to drugs. Antibiotics like penicillins, cephalosporins, and trimethoprim are safe for breastfeeding mothers, as are endocrine drugs like glucocorticoids (in low doses) and levothyroxine. Epilepsy drugs like sodium valproate and carbamazepine, asthma drugs like salbutamol and theophyllines, and hypertension drugs like beta-blockers and hydralazine are also safe. Anticoagulants like warfarin and heparin, as well as digoxin, are also safe. However, some drugs should be avoided, such as antibiotics like ciprofloxacin, tetracycline, chloramphenicol, and sulphonamides, psychiatric drugs like lithium and benzodiazepines, aspirin, carbimazole, methotrexate, sulfonylureas, cytotoxic drugs, and amiodarone. Other contraindications include galactosaemia and viral infections, although the latter is controversial in the developing world due to the increased risk of infant mortality and morbidity associated with bottle feeding.

According to the GMC guidelines in good medical practice for individuals aged 0-18 years, it is important to disclose information regarding any abusive or seriously harmful sexual activity involving a child or young person. This includes situations where the young person is too immature to understand or consent, there are significant differences in age, maturity, or power between sexual partners, the young person’s sexual partner holds a position of trust, force or the threat of force, emotional or psychological pressure, bribery or payment is used to engage in sexual activity or keep it secret, drugs or alcohol are used to influence a young person to engage in sexual activity, or the person involved is known to the police or child protection agencies for having abusive relationships with children or young people.

Failing to disclose this information or simply prescribing contraception and waiting for a review can put both the patient and other students at the boyfriend’s school in harm’s way due to his position of trust. While informing the boyfriend or his school may breach confidentiality and not address the issue of his job and relationship, it is important to take appropriate action to protect the safety and well-being of the young person involved.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

The addition of progesterone to hormone replacement therapy (HRT) has been found to raise the risk of breast cancer. It is worth noting that taking low doses of progesterone alone, without oestrogen, does not seem to have the same effect on breast cancer risk. If used for less than 10 years, oestrogen-only HRT does not appear to increase the likelihood of developing breast cancer. However, it does increase the risk of endometrial cancer and should be avoided unless the patient has had a hysterectomy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Risk Factors for Cervical Carcinoma: Understanding the Role of Smoking, HPV, and Other Factors

Cervical carcinoma is a type of cancer that affects the cervix, the lower part of the uterus. While the exact causes of cervical carcinoma are not fully understood, several risk factors have been identified. In this article, we will explore some of the key risk factors associated with the development of cervical carcinoma, including smoking, HPV infection, late menopause, nulliparity, obesity, and the use of contraceptive pills.

Smoking is a significant risk factor for cervical carcinoma, accounting for 21% of cases in the UK. Nicotine and cotinine, two chemicals found in tobacco smoke, may directly damage DNA in cervical cells and act as a cofactor in HPV-driven carcinogenesis.

Persistent infection with HPV is the strongest risk factor for cervical carcinoma. Other risk factors include early sexual activity, low socio-economic status, co-infection with HIV, immunosuppression, and a family history of cervical carcinoma. Late menopause is a known risk factor for ovarian and endometrial carcinoma, but not cervical carcinoma. Nulliparity is associated with ovarian and endometrial carcinoma, but not cervical carcinoma. Obesity is a risk factor for endometrial carcinoma, but not cervical carcinoma.

The combined oral contraceptive pill has been associated with a small increase in the risk of developing cervical carcinoma, but there is no evidence to support an association with the progesterone-only pill.

In conclusion, understanding the risk factors associated with cervical carcinoma is important for prevention and early detection. Quitting smoking, practicing safe sex, and getting regular cervical cancer screenings can help reduce the risk of developing this type of cancer.

If a cervical cancer screening sample is positive for high-risk strains of human papillomavirus (hrHPV) but shows no cytological abnormalities, the recommended course of action is to repeat the smear after 12 months. This is in accordance with current guidance. Colposcopy is not necessary in this case. Repeating the smear after 3 months or waiting 3 years for routine recall are also not appropriate. A repeat smear after 6 months would only be necessary after treatment for cervical intraepithelial neoplasia.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The addition of progesterone to HRT increases the likelihood of developing breast cancer, but this risk is dependent on the duration of treatment and decreases after HRT is discontinued. However, it does not affect the risk of dying from breast cancer. HRT with only oestrogen is linked to a lower risk of coronary heart disease, while combined HRT has a minimal or no impact on CHD risk. progesterone-only HRT is not available. NICE does not provide a specific risk assessment for ovarian cancer in women taking HRT, but refers to a meta-analysis indicating an increased risk for both oestrogen-only and combined HRT preparations.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

When it is necessary to stop breastfeeding, Cabergoline is the preferred medication for suppressing lactation. This is because Cabergoline is a dopamine receptor agonist that can inhibit the production of prolactin, which in turn suppresses lactation. It should be noted that Norethisterone has no effect on lactation, Misoprostol is used to soften the cervix during labor induction, and Ursodeoxycholic acid is a bile acid chelating agent used to treat cholestasis in pregnancy.

Techniques for Suppressing Lactation during Breastfeeding

Breastfeeding is a natural process that provides essential nutrients to newborns. However, there may be situations where a mother needs to suppress lactation. This can be achieved by stopping the lactation reflex, which involves stopping suckling or expressing milk. Additionally, supportive measures such as wearing a well-supported bra and taking analgesia can help alleviate discomfort. In some cases, medication may be required, and cabergoline is the preferred choice. By following these techniques, lactation can be suppressed effectively and safely.

Based on the given history, it appears that there is a blockage preventing the normal flow of menstrual blood. This is indicated by the presence of secondary sexual characteristics and recurring abdominal pain. It can be ruled out that the cause of this condition is a bicornuate uterus, dermoid cysts, endometriosis, or pelvic inflammatory disease, as these are not associated with primary amenorrhoea.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

The addition of progesterone to hormone replacement therapy (HRT) has been linked to an increased risk of breast cancer, as well as venous thromboembolism and cardiovascular disease. HRT may be recommended for menopausal patients experiencing vasomotor symptoms such as hot flashes, night sweats, and palpitations. However, if a patient only presents with urogenital symptoms, topical oestrogens such as oestradiol creams or pessaries may be more appropriate. These act locally to alleviate vaginal dryness, reduce UTI recurrence, and ease dyspareunia. For patients with vasomotor symptoms, HRT preparations with systemic effects (such as oral medications, topical patches, and implants) may be considered. If the patient has not undergone a hysterectomy, their HRT regime must include both oestrogen and progesterone to prevent hypertrophy of the uterus and a 5-10x increased risk of endometrial carcinoma associated with unopposed oestrogen therapy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

The COCP should not be prescribed in the first 21 days post-partum due to the increased risk of venous thromboembolism. Breastfeeding patients should use caution when taking the COCP. Physiological parameters return to normal by 3 months post-partum, but it would be inappropriate to make the patient wait that long to resume the COCP. Pregnancy is a hypercoagulable state, increasing the risk of venous thromboembolism.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Distinguishing between common vaginal infections: Trichomoniasis, Bacterial Vaginosis, gonorrhoeae, Chlamydia, and Mycoplasma Genitalium

When a woman presents with an elevated vaginal pH, a fish-smelling, yellow vaginal discharge, and ovoid trichomonads, the diagnosis of trichomoniasis (Trichomonas vaginalis) is strongly supported. A wet saline mount or anaerobic culture can confirm the diagnosis, with culture being particularly useful in men. Treatment involves oral metronidazole for seven days or a single 2g dose, and sexual partners should also be treated to prevent re-infection.

Bacterial vaginosis is a differential diagnosis to consider, as it also presents with a fish-smelling discharge and a pH > 4.5. However, the presence of ovoid mobile parasites on wet saline mount suggests trichomoniasis as the more likely diagnosis. Bacterial vaginosis would show clue cells on wet saline mount.

gonorrhoeae and Chlamydia are sexually transmitted infections that are more likely to be seen in patients with a history of unprotected sex. However, fish-smelling discharge is not characteristic of either infection. A specimen culture of gonorrhoeae would show Gram-negative diplococci, while chlamydia would not show ovoid mobile parasites on wet saline mount.

Mycoplasma genitalium is another potential sexually transmitted infection that can cause urethritis, discharge, cervicitis, or endometritis in women. However, the wet saline mount results suggest that this is not the diagnosis, and fish-smelling discharge is not characteristic of this infection.

In summary, a combination of clinical presentation, wet saline mount, and culture can help distinguish between common vaginal infections such as trichomoniasis, bacterial vaginosis, gonorrhoeae, chlamydia, and mycoplasma genitalium.

progesterone Only Pill: What to Do When You Miss a Pill

The progesterone only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to note that the rules for the two types of pills should not be confused. The traditional POPs (Micronor, Noriday, Norgeston, Femulen) and Cerazette (desogestrel) have the following guidelines for missed pills:

– If the pill is less than 3 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 3 hours late (i.e., more than 27 hours since the last pill was taken), action is needed.
– If the pill is less than 12 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 12 hours late (i.e., more than 36 hours since the last pill was taken), action is needed.

Management of Ectopic Pregnancy: Laparoscopic Salpingostomy

Ectopic pregnancy, defined as pregnancy occurring outside the uterine cavity, is a serious condition that requires prompt diagnosis and management. Laparoscopic salpingostomy is a preferred method of treatment for ectopic pregnancies, but it may not be suitable for all cases.

Diagnosis of ectopic pregnancy can be challenging as it presents with non-specific symptoms such as lower abdominal/pelvic pain, vaginal discharge, and urinary symptoms. A urinary pregnancy test and an ultrasound scan are necessary to confirm the diagnosis. In emergency cases where the patient is haemodynamically unstable, laparotomy may be necessary.

Laparoscopic salpingectomy, the removal of the tube containing the ectopic pregnancy, is the gold standard for treating ectopic pregnancies. However, if the patient has only one Fallopian tube, laparoscopic salpingostomy, where the tube is incised, the ectopic removed, and the tube repaired, is preferred to preserve the patient’s chances of conceiving naturally in the future.

A single intramuscular dose of methotrexate may be used as medical management of an ectopic pregnancy, but only if certain conditions are met. These include the absence of significant pain, an unruptured ectopic pregnancy, and a serum βhCG level of <1500 iu/l. In cases where right iliac fossa pain is present in a woman of reproductive age, associated with vaginal discharge, cervical excitation, and the last menstrual period of >4 weeks before, ectopic pregnancy should be treated as the primary diagnosis until proven otherwise. Referral to the surgical team may be necessary to rule out appendicitis.

In conclusion, laparoscopic salpingostomy is a suitable method of treatment for ectopic pregnancies in patients with only one Fallopian tube. Early diagnosis and prompt management are crucial in ensuring the best possible outcome for the patient.

Pregnant women with a BMI greater than 30 kg/m2 should be prescribed a high dose of 5mg folic acid instead of the standard 400 micrograms. Therefore, the lifestyle and dietary advice given to this patient is incorrect. Additionally, prescribing 75 mg of aspirin is not appropriate for this patient as it is typically given to women with one high-risk factor or two moderate-risk factors for pre-eclampsia, and a BMI over 35 would only qualify as a single moderate-risk factor. While 150 mg of aspirin is an alternative dose for pre-eclampsia prophylaxis, 75 mg is more commonly used in practice.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

Diagnosis of Androgen Insensitivity Syndrome: A Case Study

The presented case strongly suggests the presence of androgen insensitivity syndrome, a condition where a patient’s phenotype and secondary sexual characteristics differ from their karyotype and gonads. In this case, the patient is likely to have a karyotype of 46,XY and be a male pseudohermaphrodite. Androgen insensitivity syndrome is associated with mutations in the AR gene, which codes for the androgen receptor. In complete androgen insensitivity, the body cannot respond to androgens at all, resulting in a female phenotype, female secondary sexual characteristics, no uterus, and undescended testes.

Karyotyping is the key diagnostic investigation to confirm the diagnosis of androgen insensitivity syndrome. Serum oestradiol levels may vary according to the type of androgen insensitivity disorder and are unlikely to aid the diagnosis. Pituitary MRI may be a second diagnostic investigation if karyotype abnormalities are ruled out. Transvaginal ultrasound is not necessary if an abdominal ultrasound has already been performed and showed an absent uterus.

Clomiphene is the recommended first-line treatment for infertility in patients with PCOS. While there is ongoing debate about the use of metformin, current evidence does not support it as a first-line option. In vitro fertilisation is also not typically used as a first-line treatment for PCOS-related infertility.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is associated with high levels of luteinizing hormone and hyperinsulinemia. Management of PCOS is complex and varies depending on the individual’s symptoms. Weight reduction is often recommended, and a combined oral contraceptive pill may be used to regulate menstrual cycles and manage hirsutism and acne. If these symptoms do not respond to the pill, topical eflornithine or medications like spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another common issue associated with PCOS. Weight reduction is recommended, and the management of infertility should be supervised by a specialist. There is ongoing debate about the most effective treatment for infertility in patients with PCOS. Clomiphene is often used, but there is a potential risk of multiple pregnancies with anti-oestrogen therapies like Clomiphene. Metformin is also used, either alone or in combination with Clomiphene, particularly in patients who are obese. Gonadotrophins may also be used to stimulate ovulation. The Royal College of Obstetricians and Gynaecologists (RCOG) published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS.

Medical abortions involve the use of mifepristone followed by at least one dose of prostaglandins and can be performed at any stage of pregnancy. The preferred method is oral mifepristone followed by vaginal administration of prostaglandins, such as misoprostol. This method is particularly suitable for pregnancies up to 7 weeks gestation, as it has a lower failure rate than surgical termination. The dosing schedule and location of administration may vary, with some women choosing to undergo the procedure at home rather than in a clinic. It is important to note that IM methotrexate is not used in terminations of pregnancy, but rather in the medical management of ectopic pregnancies, as well as in the treatment of certain cancers and rheumatoid conditions. Methotrexate and vaginal misoprostol is not a common combination for medical terminations, as mifepristone is typically used instead. Oral mifepristone alone is not sufficient for medical terminations, but may be used in cervical priming for surgical abortion in cases where misoprostol is contraindicated.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Although clinical features such as infrequent or absent ovulation and hyperandrogenism can suggest PCOS, NICE CKS recommends using specific diagnostic criteria. To diagnose PCOS, at least 2 out of 3 of the following criteria should be present: infrequent or no ovulation, signs of hyperandrogenism or elevated testosterone levels, and polycystic ovaries or increased ovarian volume on ultrasonography. It is important to note that a high BMI is not part of the diagnostic criteria, but signs of insulin resistance such as acanthosis nigricans may aid in diagnosis.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

The UK Medical Eligibility Criteria (UKMEC) offer guidance on the contraindications for using contraception, including the combined oral contraceptive pill (COCP). The UKMEC categorizes the use of COCP as follows: no restriction (UKMEC1), advantages outweigh disadvantages (UKMEC2), disadvantages outweigh advantages (UKMEC3), and unacceptable risk (UKMEC4).

According to UKMEC3, COCP use may have more disadvantages than advantages for individuals who are over 35 years old and smoke less than 15 cigarettes per day, have a BMI over 35, experience migraines without aura, have a family history of deep vein thrombosis or pulmonary embolism in a first-degree relative under 45 years old, have controlled hypertension, are immobile (e.g., use a wheelchair), or are breastfeeding and between 6 weeks to 6 months postpartum.

On the other hand, UKMEC4 indicates that COCP use poses an unacceptable risk for individuals who are over 35 years old and smoke more than 15 cigarettes per day, experience migraines with aura, have a personal history of deep vein thrombosis or pulmonary embolism, have a personal history of stroke or ischemic heart disease, have uncontrolled hypertension, have breast cancer, have recently undergone major surgery with prolonged immobilization, or are breastfeeding and less than 6 weeks postpartum.

Source: FSRH UKMEC for contraceptive use.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

When a cervical cancer screening smear is inadequate, the recommended course of action is to repeat the smear within 3 months. It is not necessary to consider any previous inadequate smears from a decade ago. Therefore, repeating the smear in 1 month or 3 years is not appropriate. Referral for colposcopy or gynaecology is also not necessary at this stage, as it should only be considered if the second smear in 3 months’ time is also inadequate.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Differential diagnosis of abdominal symptoms

Abdominal symptoms can have various causes, and a careful differential diagnosis is necessary to identify the underlying condition. In this case, the patient presents with bloating, early satiety, urinary symptoms, and an elevated CA-125 level. Here are some possible explanations for these symptoms, based on their typical features and diagnostic markers.

Ovarian cancer: This is a possible diagnosis, given the mass effect on the gastrointestinal and urinary organs, as well as the elevated CA-125 level. However, ovarian cancer often presents with vague symptoms initially, and other conditions can also increase CA-125 levels. Anorexia and weight loss are additional symptoms to consider.

Colorectal cancer: This is less likely, given the absence of typical symptoms such as change in bowel habits, rectal bleeding, or anemia. The classical marker for colorectal cancer is CEA, not CA-125.

Irritable bowel syndrome: This is also less likely, given the age of the patient and the presence of urinary symptoms. Irritable bowel syndrome is a diagnosis of exclusion, and other likely conditions should be ruled out first.

Genitourinary prolapse: This is a possible diagnosis, given the urinary symptoms and the sensation of bulging or fullness. Vaginal spotting, pain, or irritation are additional symptoms to consider. However, abdominal bloating and early satiety are not typical, and CA-125 levels should not be affected.

Diverticulosis: This is unlikely, given the absence of typical symptoms such as altered bowel habits or left iliac fossa pain. Diverticulitis can cause rectal bleeding, but fever and acute onset of pain are more characteristic.

In summary, the differential diagnosis of abdominal symptoms should take into account the patient’s age, gender, medical history, and specific features of the symptoms. Additional tests and imaging may be necessary to confirm or exclude certain conditions.

If a cervical smear test performed as part of the NHS cervical screening programme returns as hr HPV positive, cytology is performed. If the cytology shows normal cells, the test is repeated in 12 months. If the second repeat test is still hr HPV positive and cytology normal, the test should be repeated in a further 12 months. However, if the third test at 24 months is still hr HPV positive, colposcopy should be performed instead of returning the patient to routine recall. Repeating the test in 3, 6 or 12 months is not appropriate in this case.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hr HPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Treatment Options for Symptomatic Cystocoele: Lifestyle Modifications, Medications, and Surgeries

Symptomatic cystocoele can be treated through various options, depending on the severity of the condition. The first line of treatment focuses on lifestyle modifications, such as smoking cessation and weight loss. Topical oestrogen may also be prescribed to post- or perimenopausal women suffering from vaginal dryness, urinary incontinence, recurrent urinary tract infections, or superficial dyspareunia. Inserting a ring pessary is the second line of treatment, which needs to be changed every six months and puts the patient at risk of ulceration. Per vaginal surgery is the third line of treatment, which is only possible if the cystocoele is small and puts the patient at risk of fibroids and adhesions. Hysterectomy is not recommended as it increases the risk of cystocoele due to the severance of the uterine ligaments and reduction in support following removal of the uterus.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Treatment Options for Pelvic Inflammatory Disease (PID)

Pelvic inflammatory disease (PID) is a common condition caused by the ascending infection of Chlamydia or gonorrhoeae from the vagina. The symptoms include bilateral lower abdominal pain, deep dyspareunia, and abnormal bleeding or discharge. The recent British Association for Sexual Health and HIV (BASHH) guideline recommends empirical antibiotic treatment for sexually active women under 25 who have these symptoms. The treatment includes stat im ceftriaxone and a 2-week course of doxycycline and metronidazole. Intravenous therapy is indicated in severe cases.

Pelvic ultrasound scan is not necessary for the diagnosis of PID. Blood tests to check inflammatory markers and serum β-HCG are not required if the clinic history and examination suggest PID. Analgesia and observation are not sufficient for the treatment of PID. Oral antibiotics alone are not recommended for the treatment of PID.

In conclusion, PID requires prompt and appropriate treatment with broad-spectrum antibiotics. The recommended treatment options should be followed based on the severity of the disease.

Prolapse refers to the descent of pelvic organs into the vagina, which can be categorized into different degrees. First-degree prolapse involves the descent of the uterus and cervix, but they do not reach the vaginal opening. Second-degree prolapse is when the cervix descends to the level of the introitus. Third-degree prolapse is the protrusion of the cervix and uterus outside of the vagina. Fourth-degree prolapse is the complete prolapse of the cervix, uterus, and vaginal wall, which can cause bleeding due to cervix ulceration. Vault prolapse is the prolapse of the top of the vagina down the vaginal canal, often occurring after a hysterectomy due to weakness of the upper vagina. The causes of urogenital prolapse are multifactorial and can include factors such as childbirth, menopause, chronic cough, obesity, constipation, and suprapubic surgery for urinary continence.

If pelvic floor muscle exercises and surgical intervention are not effective, duloxetine can be used to treat stress incontinence in patients. However, it is important to rule out other potential causes such as infection before starting treatment. Non-pharmacological management should be attempted first, including pelvic floor exercises and reducing caffeine intake. Duloxetine is a medication that works as a serotonin/norepinephrine reuptake inhibitor and may cause side effects such as nausea, dizziness, and insomnia. For urge incontinence, antimuscarinic agents like oxybutynin, tolterodine, and solifenacin are typically used as first-line treatment. If these are not effective, a β3 agonist called mirabegron can be used as a second-line therapy.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

For cervical cancer screening, if the first repeat smear test after 12 months shows a negative result for high risk HPV (hrHPV), the patient can return to routine recall. However, if the initial smear test shows a positive result for hrHPV but is cytologically normal, the patient will be called back for a repeat test after 12 months. If the second test also shows a negative result for hrHPV, the patient can return to normal recall. On the other hand, if the second test is still positive for hrHPV but cytologically normal, it will be repeated again after 12 months.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.